Aleris acquired by Mehiläinen Group
Context
Mehiläinen Group acquired 100% of Aleris Group from Triton Partners in a transformational pan-European healthcare transaction. The deal was structured via a definitive share purchase agreement that pooled institutional equity from Mehiläinen's financial sponsors, CVC Capital Partners and Hellman & Friedman, alongside tailored cross-border corporate debt facilities. While the exact financial terms of the purchase price remained undisclosed, the transaction successfully integrated Aleris into Mehiläinen’s international operations as a distinct, specialized care platform. Under the binding terms of the agreement, Aleris Group CEO Sofia Palmquist retains her operational leadership role to ensure regional business continuity alongside Mehiläinen Group CEO Janne-Olli Järvenpää. This acquisition immediately expands Mehiläinen’s Scandinavian footprint into Norway and Denmark while drastically scaling its existing Swedish Meliva brand, creating a combined healthcare powerhouse with 60,000 professionals across 1,500 locations positioned to deliver highly integrated, digitally powered outpatient care pathways across Europe.
In the past, Aleris was acquired by Triton Partners in 2019 as part of its expansion strategy.
Aleris, which reported an EBITDA margin of [members only] in 2025, is valued in this transaction at an EV/EBITDA multiple of [members only].
-> Deep-dive in Healthcare & Pharma market trends
Target
Aleris Group is a premier Scandinavian healthcare provider specializing in high-quality elective surgery, outpatient mental health services, and medical diagnostics. Headquartered in Stockholm, Sweden, the company operates via a multi-payer economic model, serving roughly millions patient visits annually through public healthcare system allocations, private health insurance programs, and out-of-pocket direct payments. The organization runs a unified network of approximately +100 clinics and hospitals staffed by +5,000 specialized medical professionals across Sweden, Norway, and Denmark. Strategically, the firm acts as a dominant, high-equity clinical complement to publicly funded healthcare systems, utilizing advanced digital infrastructure to streamline outpatient care pathways.
Ent. Value
[members only]
Equity Value
[members only]
Multiples
EV / Revenue
[members only]
EV / EBITDA
[members only]
EV / EBIT
[members only]
Historical Financials (SEK)
Other operations with Aleris
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 07/2019 | TRITON PARTNERS | ALERIS | SWEDEN | Clinics / Hospitals |
Similar deals in Health Providers
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 09/2026 | BRIDGEPOINT | ALTANO | GERMANY | Vet Clinics |
| 06/2026 | STAR CAPITAL | GLENHOLME SPECIALIST CARE | UNITED KINGDOM | Nursing Homes |
| 05/2026 | KINDERHOOK INDUSTRIES | ENHABIT | UNITED STATES | Clinics / Hospitals |
| 05/2026 | STONEPEAK | ESTIA HEALTH | AUSTRALIA | Nursing Homes |
| 05/2026 | JARDINE MATHESON | I-MED RADIOLOGY NETWORK | AUSTRALIA | Radiology |
| 04/2026 | COLOSSEUM DENTAL GROUP | MEDICALSAN | ITALY | Dental Centers |
| 03/2026 | CAPITON | SAPV CARE | GERMANY | Outpatient Care |
| 02/2026 | MERIEUX EQUITY PARTNERS | HEALTH IN CODE (HIC) | SPAIN | Labs (Biology) |
| 01/2026 | GTCR | DENTALCORP | CANADA | Dental Centers |
| 01/2026 | POINT VISION | CLINIQUE DE LA VISION (REFRACT SAS) | FRANCE | Ophthalmology |
REFERENCES
Revenue range: REV SEK 1–10bn
Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of Aleris by Mehiläinen Group are reserved for mynth community members. Register for free to unlock full data.
Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.
FAQ
What transaction does this page cover?
What was Aleris’s revenue at the time of the deal?
What sources support the information on this transaction?
What is mynth?